{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T08:01:59Z","timestamp":1780041719567,"version":"3.53.1"},"reference-count":73,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T00:00:00Z","timestamp":1782864000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,7]]},"DOI":"10.1016\/j.critrevonc.2026.105297","type":"journal-article","created":{"date-parts":[[2026,3,25]],"date-time":"2026-03-25T18:56:15Z","timestamp":1774464975000},"page":"105297","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Chemotherapy in dedifferentiated chondrosarcoma: From neoadjuvant to palliative treatment options"],"prefix":"10.1016","volume":"223","author":[{"given":"Piotr","family":"Remiszewski","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"W\u0105\u017c","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S\u0142awomir","family":"Falkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Rutkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna M.","family":"Czarnecka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2026.105297_bib1","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/s00428-014-1685-4","article-title":"Isocitrate dehydrogenase 1 mutations (IDH1) and p16\/CDKN2A copy number change in conventional chondrosarcomas","volume":"466","author":"Amary","year":"2014","journal-title":"Virchows Arch."},{"key":"10.1016\/j.critrevonc.2026.105297_bib2","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1002\/jor.24463","article-title":"Survival and prognosis of chondrosarcoma subtypes: SEER database analysis","volume":"38","author":"Amer","year":"2020","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.critrevonc.2026.105297_bib3","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1038\/onc.2011.311","article-title":"Secondary peripheral chondrosarcoma evolving from osteochondroma as a result of outgrowth of cells with functional EXT","volume":"31","author":"Andrea","year":"2011","journal-title":"Oncogene"},{"key":"10.1016\/j.critrevonc.2026.105297_bib4","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1245\/s10434-015-4852-1","article-title":"Metastatic potential of grade I chondrosarcoma of bone: results of a multi-institutional study","volume":"23","author":"Andreou","year":"2015","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib5","doi-asserted-by":"crossref","first-page":"749","DOI":"10.3109\/17453674.2011.636668","article-title":"Survival and prognostic factors in chondrosarcoma","volume":"82","author":"Andreou","year":"2011","journal-title":"Acta Orthop."},{"key":"10.1016\/j.critrevonc.2026.105297_bib6","doi-asserted-by":"crossref","first-page":"155","DOI":"10.6004\/jnccn.2017.0017","article-title":"NCCN guidelines insights: bone cancer, version 2.2017","volume":"15","author":"Biermann","year":"2017","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.critrevonc.2026.105297_bib7","article-title":"Bone cancer, Version 2.2025, NCCN clinical practice guidelines in oncology","volume":"23","author":"Biermann","year":"2025","journal-title":"J. Natl. Compr. Cancer Netw."},{"key":"10.1016\/j.critrevonc.2026.105297_bib8","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1097\/CORR.0000000000000748","article-title":"Does the SORG algorithm predict 5-year survival in patients with chondrosarcoma? An external validation","volume":"477","author":"Bongers","year":"2019","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.critrevonc.2026.105297_bib9","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1038\/nrc2869","article-title":"Cartilage tumours and bone development: molecular pathology and possible therapeutic targets","volume":"10","author":"Bov\u00e9e","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105297_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.mpdhp.2014.03.001","article-title":"Histologic variants of chondrosarcoma","volume":"20","author":"Chebib","year":"2014","journal-title":"Diagn. Histopathol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib11","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1097\/CORR.0000000000002011","article-title":"Is chemotherapy associated with improved overall survival in patients with dedifferentiated chondrosarcoma? A SEER database analysis","volume":"480","author":"Cranmer","year":"2022","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.critrevonc.2026.105297_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.111096","article-title":"Efficacy of perioperative chemotherapy and radiotherapy in patients diagnosed with mesenchymal and dedifferentiated chondrosarcoma","volume":"51","author":"Czarnecka","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105297_bib13","first-page":"922","article-title":"Dedifferentiated chondrosarcoma with minimal or small dedifferentiated component","volume":"35","author":"Dehner","year":"2022","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.critrevonc.2026.105297_bib14","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.2106\/00004623-200411000-00008","article-title":"Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes","volume":"86","author":"Dickey","year":"2004","journal-title":"J. Bone Jt. Surg. Am."},{"key":"10.1016\/j.critrevonc.2026.105297_bib15","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1097\/00019606-199312000-00005","article-title":"Possible association of p53 overexpression and mutation with high-grade chondrosarcoma","volume":"2","author":"Dobashi","year":"1993","journal-title":"Diagn. Mol. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib16","doi-asserted-by":"crossref","DOI":"10.1002\/ijc.70023","article-title":"Metastatic chondrosarcoma, patterns of care, and outcomes of patients in a real-life national setting over a decade","author":"Ducrot","year":"2025","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105297_bib17","doi-asserted-by":"crossref","first-page":"4581","DOI":"10.3390\/cancers15184581","article-title":"Mesenchymal chondrosarcoma from diagnosis to clinical trials","volume":"15","author":"Dudzisz-\u015aled\u017a","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105297_bib18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1200\/JCO.1987.5.1.21","article-title":"Adjuvant chemotherapy for osteosarcoma: a randomized prospective trial","volume":"5","author":"Eilber","year":"1987","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib19","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.2106\/00004623-198668080-00008","article-title":"Dedifferentiated chondrosarcoma. A report of the clinicopathological features and treatment of seventy-eight cases","volume":"68","author":"Frassica","year":"1986","journal-title":"J. Bone Jt. Surg."},{"key":"10.1016\/j.critrevonc.2026.105297_bib20","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1186\/s12885-018-4741-7","article-title":"Survival and prognostic factors in conventional central chondrosarcoma","volume":"18","author":"Fromm","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2026.105297_bib21","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1016\/j.prp.2017.04.019","article-title":"Dedifferentiated chondrosarcoma with \u201cadamantinoma-like\u201d features: a case report and review of literature","volume":"213","author":"Gambarotti","year":"2017","journal-title":"Pathol. - Res. Pr."},{"key":"10.1016\/j.critrevonc.2026.105297_bib22","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41416-024-02868-4","article-title":"UK guidelines for the management of bone sarcomas","volume":"132","author":"Gerrand","year":"2024","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105297_bib23","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2021.746909","article-title":"Dedifferentiated central chondrosarcoma: a clinical, histopathological, and immunohistochemical analysis of 57 cases","volume":"8","author":"Gong","year":"2021","journal-title":"Front. Med."},{"key":"10.1016\/j.critrevonc.2026.105297_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.jbo.2022.100456","article-title":"Appendicular dedifferentiated chondrosarcoma: a management and survival study from the SEER database","volume":"37","author":"Gonzalez","year":"2022","journal-title":"J. Bone Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib25","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1016\/j.ejca.2007.06.016","article-title":"Dedifferentiated chondrosarcoma: prognostic factors and outcome from a European group","volume":"43","author":"Grimer","year":"2007","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105297_bib26","doi-asserted-by":"crossref","first-page":"35448","DOI":"10.52965\/001c.35448","article-title":"Dedifferentiated chondrosarcoma: a case series and review of the literature","volume":"14","author":"Gusho","year":"2022","journal-title":"Orthop. Rev."},{"key":"10.1016\/j.critrevonc.2026.105297_bib27","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.ejca.2021.04.017","article-title":"Outcome in dedifferentiated chondrosarcoma for patients treated with multimodal therapy: results from the EUROpean bone over 40 sarcoma study","volume":"151","author":"Hompland","year":"2021","journal-title":"Eur. J. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105297_bib28","doi-asserted-by":"crossref","first-page":"4250","DOI":"10.21037\/tcr-20-357","article-title":"Treatment method and prognostic factors of chondrosarcoma: based on Surveillance, Epidemiology, and End Results (SEER) database","volume":"9","author":"Hua","year":"2020","journal-title":"Transl. Cancer Res."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105297_bib29","article-title":"Prognostic significance of percentage and size of dedifferentiation in dedifferentiated chondrosarcoma","volume":"36","author":"Hung","year":"2023","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.critrevonc.2026.105297_bib30","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/annonc\/mdt374","article-title":"Advanced chondrosarcomas: role of chemotherapy and survival","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib31","doi-asserted-by":"crossref","first-page":"2916","DOI":"10.1093\/annonc\/mdt374","article-title":"Advanced chondrosarcomas: role of chemotherapy and survival","volume":"24","author":"Italiano","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib32","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-026-68716-6","article-title":"Olutasidenib in recurrent\/relapsed locally advanced or metastatic IDH1-mutated chondrosarcoma: phase 1b\/2 trial","author":"Jones","year":"2026","journal-title":"Nat. Commun."},{"key":"10.1016\/j.critrevonc.2026.105297_bib33","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1007\/s11999-013-3360-5","article-title":"Does ifosfamide therapy improve survival of patients with dedifferentiated chondrosarcoma?","volume":"472","author":"Kawaguchi","year":"2013","journal-title":"Clin. Orthop. Relat. Res."},{"key":"10.1016\/j.critrevonc.2026.105297_bib34","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.3390\/cancers15061703","article-title":"Classification of chondrosarcoma: from characteristic to challenging imaging findings","volume":"15","author":"Kim","year":"2023","journal-title":"Cancers"},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105297_bib35","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/modpathol.2016.108","article-title":"Analysis of PD-L1, T-cell infiltrate and HLA expression in chondrosarcoma indicates potential for response to immunotherapy specifically in the dedifferentiated subtype","volume":"29","author":"Kostine","year":"2016","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib36","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1111\/cas.15382","article-title":"Clinical features and treatment outcomes of dedifferentiated and grade 3 chondrosarcoma: a multi-institutional study","volume":"113","author":"Kozawa","year":"2022","journal-title":"Cancer Sci."},{"key":"10.1016\/j.critrevonc.2026.105297_bib37","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s13569-018-0110-1","article-title":"Dedifferentiated chondrosarcoma of the pelvis: clinical outcomes and current treatment","volume":"8","author":"Lex","year":"2018","journal-title":"Clin. Sarcoma Res."},{"key":"10.1016\/j.critrevonc.2026.105297_bib38","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1186\/s13018-024-05098-9","article-title":"The clinical outcomes and prognostic factors of dedifferentiated central chondrosarcoma in extremities","volume":"19","author":"Li","year":"2024","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.critrevonc.2026.105297_bib39","article-title":"Dedifferentiated chondrosarcoma: radiological features, prognostic factors and survival statistics in 23 patients","volume":"12","author":"Liu","year":"2017","journal-title":"PLOS ONE"},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105297_bib40","first-page":"435","article-title":"H3K27me3 deficiency defines a subset of dedifferentiated chondrosarcomas with characteristic clinicopathological features","volume":"32","author":"Makise","year":"2019","journal-title":"Mod. Pathol. Off. J. U. S. Can. Acad. Pathol. Inc."},{"key":"10.1016\/j.critrevonc.2026.105297_bib41","first-page":"110","article-title":"Outcome of first-line systemic treatment for unresectable conventional, dedifferentiated, mesenchymal, and clear cell chondrosarcoma","volume":"24","author":"Maldegem","year":"2018","journal-title":"Oncology"},{"key":"10.1016\/j.critrevonc.2026.105297_bib42","doi-asserted-by":"crossref","DOI":"10.1155\/2019\/9069272","article-title":"Prognostic factors in dedifferentiated chondrosarcoma: a retrospective analysis of a large series treated at a single institution","volume":"2019","author":"Miao","year":"2019","journal-title":"Sarcoma"},{"key":"10.1016\/j.critrevonc.2026.105297_bib43","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1302\/0301-620X.82B1.0820055","article-title":"Experience in the treatment of dedifferentiated chondrosarcoma","volume":"82","author":"Mitchell","year":"2000","journal-title":"J. Bone Jt. Surg."},{"key":"10.1016\/j.critrevonc.2026.105297_bib44","doi-asserted-by":"crossref","first-page":"9369","DOI":"10.1200\/JCO.2005.03.7127","article-title":"MYC amplification and polysomy 8 in chondrosarcoma: array comparative genomic hybridization, fluorescent in situ hybridization, and association with outcome","volume":"23","author":"Morrison","year":"2005","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib45","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/jor.24030","article-title":"C-reactive protein: an independent predictor for dedifferentiated chondrosarcoma","volume":"36","author":"Nemecek","year":"2018","journal-title":"J. Orthop. Res."},{"key":"10.1016\/j.critrevonc.2026.105297_bib46","doi-asserted-by":"crossref","first-page":"1200","DOI":"10.1136\/jcp.2005.029629","article-title":"Dedifferentiated chondrosarcoma with telangiectatic osteosarcoma-like features","volume":"59","author":"Okada","year":"2006","journal-title":"J. Clin. Pathol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105297_bib47","doi-asserted-by":"crossref","first-page":"1347","DOI":"10.1016\/j.ajpath.2012.12.036","article-title":"Screening for potential targets for therapy in mesenchymal, clear cell, and dedifferentiated chondrosarcoma reveals Bcl-2 family members and TGF\u03b2 as potential targets","volume":"182","author":"Oosterwijk","year":"2013","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib48","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/BF01221195","article-title":"Metastasis of chondrosarcoma","volume":"122","author":"Ozaki","year":"1996","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib49","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2020.38.15_suppl.11522","article-title":"IMMUNOSARC: a collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I\/II trial of sunitinib and nivolumab in advanced soft tissue and bone sarcoma: results from the phase II part, bone sarcoma cohort","volume":"38","author":"Palmerini","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib50","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1007\/s11912-024-01630-6","article-title":"Neoadjuvant or adjuvant chemotherapy in soft-tissue sarcoma?","volume":"27","author":"Remiszewski","year":"2025","journal-title":"Curr. Oncol. Rep."},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105297_bib51","doi-asserted-by":"crossref","first-page":"615","DOI":"10.3390\/curroncol32110615","article-title":"Chemotherapy strategies and their efficacy for mesenchymal chondrosarcoma","volume":"32","author":"Remiszewski","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib52","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.jos.2020.04.013","article-title":"Pathological fracture does not affect prognosis in dedifferentiated chondrosarcoma of the limbs","volume":"26","author":"Sambri","year":"2020","journal-title":"J. Orthop. Sci."},{"key":"10.1016\/j.critrevonc.2026.105297_bib53","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1111\/j.1582-4934.2008.00406.x","article-title":"Central chondrosarcoma progression is associated with pRb pathway alterations: CDK4 down-regulation and p16 overexpression inhibit cell growth in vitro","volume":"13","author":"Schrage","year":"2009","journal-title":"J. Cell. Mol. Med."},{"key":"10.1016\/j.critrevonc.2026.105297_bib54","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s00262-008-0557-7","article-title":"Chordoma and chondrosarcoma gene profile: implications for immunotherapy","volume":"58","author":"Schwab","year":"2008","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.critrevonc.2026.105297_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.991724","article-title":"Case report: treatment of metastatic dedifferentiated chondrosarcoma with pembrolizumab yields sustained complete response","volume":"12","author":"Singh","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib56","doi-asserted-by":"crossref","first-page":"2682","DOI":"10.1002\/cncr.21936","article-title":"Dedifferentiated central chondrosarcoma","volume":"106","author":"Staals","year":"2006","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105297_bib57","doi-asserted-by":"crossref","first-page":"987","DOI":"10.2106\/00004623-200705000-00010","article-title":"Dedifferentiated chondrosarcomas arising in preexisting osteochondromas","volume":"89","author":"Staals","year":"2007","journal-title":"J. Bone Jt. Surg."},{"key":"10.1016\/j.critrevonc.2026.105297_bib58","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.1002\/cncr.33618","article-title":"Ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society community of experts on the incidence threshold and the list of entities","volume":"127","author":"Stacchiotti","year":"2021","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2026.105297_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2022.102455","article-title":"Retrospective observational studies in ultra-rare sarcomas: a consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatments","volume":"110","author":"Stacchiotti","year":"2022","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2026.105297_bib60","doi-asserted-by":"crossref","first-page":"1520","DOI":"10.1016\/j.annonc.2021.08.1995","article-title":"Bone sarcomas: ESMO-EURACAN-GENTURIS-ERN PaedCan clinical practice guideline for diagnosis, treatment and follow-up","volume":"32","author":"Strauss","year":"2021","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib61","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jso.24650","article-title":"Dedifferentiated chondrosarcoma: a survival analysis of 159 cases from the SEER database (2001-2011)","volume":"116","author":"Strotman","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib62","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1002\/jso.24650","article-title":"Dedifferentiated chondrosarcoma: a survival analysis of 159 cases from the SEER database (2001-2011)","volume":"116","author":"Strotman","year":"2017","journal-title":"J. Surg. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib63","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0176972","article-title":"Efficacy and safety of gemcitabine plus docetaxel in Japanese patients with unresectable or recurrent bone and soft tissue sarcoma: results from a single-institutional analysis","volume":"12","author":"Takahashi","year":"2017","journal-title":"PLOS One"},{"key":"10.1016\/j.critrevonc.2026.105297_bib64","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1038\/ng.2668","article-title":"Frequent mutation of the major cartilage collagen gene COL2A1 in chondrosarcoma","volume":"45","author":"Tarpey","year":"2013","journal-title":"Nat. Genet."},{"key":"10.1016\/j.critrevonc.2026.105297_bib65","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.3390\/ijms24021361","article-title":"Biology and management of high-grade chondrosarcoma: an update on targets and treatment options","volume":"24","author":"Tlemsani","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.critrevonc.2026.105297_bib66","doi-asserted-by":"crossref","first-page":"566","DOI":"10.3390\/curroncol31010040","article-title":"A systematic review of adjuvant chemotherapy in localized dedifferentiated chondrosarcoma","volume":"31","author":"Tsukamoto","year":"2024","journal-title":"Curr. Oncol."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105297_bib67","doi-asserted-by":"crossref","DOI":"10.1200\/PO-24-00592","article-title":"Genomic characterization of chondrosarcoma reveals potential therapeutic targets","author":"Wagner","year":"2025","journal-title":"JCO Precis. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib68","doi-asserted-by":"crossref","DOI":"10.3389\/fsurg.2022.926008","article-title":"The clinicopathological characteristics and prognosis of young patients with chondrosarcoma of bone","volume":"9","author":"Xie","year":"2022","journal-title":"Front. Surg."},{"key":"10.1016\/j.critrevonc.2026.105297_bib69","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1749-799X-7-38","article-title":"Clinical outcome for patients with dedifferentiated chondrosarcoma: a report of 9 cases at a single institute","volume":"7","author":"Yokota","year":"2012","journal-title":"J. Orthop. Surg. Res."},{"key":"10.1016\/j.critrevonc.2026.105297_bib70","doi-asserted-by":"crossref","first-page":"2390","DOI":"10.3390\/cancers13102390","article-title":"Chondrosarcoma-from molecular pathology to novel therapies","volume":"13","author":"Zaj\u0105c","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105297_bib71","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.3390\/cancers13061317","article-title":"Biological heterogeneity of chondrosarcoma: from (Epi) genetics through stemness and deregulated signaling to immunophenotype","volume":"13","author":"Zaj\u0105c","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2026.105297_bib72","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1038\/s41379-021-00848-0","article-title":"TERT promoter mutation is an objective clinical marker for disease progression in chondrosarcoma","volume":"34","author":"Zhang","year":"2021","journal-title":"Mod. Pathol."},{"key":"10.1016\/j.critrevonc.2026.105297_bib73","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1158\/1078-0432.CCR-18-4212","article-title":"Genomic profiling identifies association of IDH1\/IDH2 mutation with longer relapse-free and metastasis-free survival in high-grade chondrosarcoma","volume":"26","author":"Zhu","year":"2019","journal-title":"Clin. Cancer Res."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001848?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826001848?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,29]],"date-time":"2026-05-29T07:06:10Z","timestamp":1780038370000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826001848"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":73,"alternative-id":["S1040842826001848"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105297","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemotherapy in dedifferentiated chondrosarcoma: From neoadjuvant to palliative treatment options","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105297","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105297"}}